Clinical Trial Search

Primary: Percentage of Participants With Successful Intravital Microscopy on Accessible Human Melanoma Tumors During Standard Local Excision — 70 percentage of participants

Primary: Overall Objective Response (Complete Response or Partial Response) — 2; 2; 15 participants

Primary: Percentage of Agreement Between the Detection of SLNs — 69.7 percentage complete agreement

Primary: Number of Participants With Suspicious Tumors Detected After Inspection of Problem Area and Inspection of the Full Body. — 810; 631 participants — p=<0.01

Primary: Clinical Response — 1; 3; 3; 2 Participants

Primary: Percentage of Participants With Relapse Free Survival — 28.6 percentage of participants

Primary: Reach of Personalized Genomic Testing for Melanoma. — 0; 204; 0; 295 Participants

Primary: Clinical Tumor Regression. — 0; 0; 6; 0 Participants

Primary: Sentinel Lymph Nodes (SLN) Mapping — 25; 25; 25; 4 Sentinel lymph nodes

Primary: Number of Participants Who Completed SSE at Specified Time Points — 217; 242; 475; 238 Participants — p=<0.001

Primary: Number of Participants That Performed a Skin Self-Examination at 3-months — 161; 185 Participants — p=0.12

Primary: Overall Tumor Response — 7; 10; 6; 12 participants

Primary: Change in Clinician Knowledge in Melanoma Risk and Lesion Identification — 72.1; 80.8 score on a scale — p=0.05

Primary: Area Under the ROC Curve (AUC) for Melanoma Detection — 0.8482 Probability area (value from 0 to 1)

Primary: Number of Participants With Treatment-Emergent Adverse Events [Safety and Tolerability] of Light-activated AU-011 — 3; 3; 3; 3 Participants

Primary: Resectability Rate — 8; 2 Participants

Primary: Objective Response Rate (ORR) of PV-10 Treated Lesions — 51.3 percentage of participants

Primary: Complete Response — 7; 3 Participants

Primary: Sensitivity and Specificity — 98.2; 9.5 Ratio * 100 — p=0.05

Primary: Immunologic Response Rate — 2; 0; 0; 3 Participants

Primary: Sun Protection Behavior Index — 3.54; 3.37 scores on a scale

Primary: Number of Patients With Treatment-emergent Adverse Events (TEAEs) — 8; 8; 0; 0 Participants

Primary: Disease-Free Survival (DFS) as Assessed Using Contrast-Enhanced Magnetic Resonance Imaging (MRI) or Contrast Enhanced Computed Tomography (CT) — NA; 36.9; 23.1; 15.4…

Primary: Determine Sensitivity of Blood-Based Assay

Primary: Pathologic Complete Response — 9 Participants

Primary: Influence of a Patient's Melanoma Diagnosis on the Survivor's and Broader Family's Skin Cancer Prevention Activity. — 24; 22; 2; 5 Participants

Primary: Number of Participants With Treatment-related Adverse Events as a Measure of Safety and Tolerability — 1; 0; 4; 2 participants

Primary: Phase I, Number of Participants With SAE and DLT — 0; 0; 1; 0 Participants

Primary: Immune Response Rate — 0.29; 0.67 proportion of participants

Primary: Level of Activated STAT1(Phospho-STAT1) — 5.96; 4.80 MU/m2 — p=.22